Moderna Trials - Search News

Merck, Moderna and cancer vaccine

Moderna stock surges as melanoma vaccine trial shows landmark moment

Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.

· 2d · on MSN

Moderna and Merck say melanoma vaccine succeeded in large trial

· 2d · on MSN

Moderna, Merck say cancer vaccine trial marks ‘landmark moment’

· 11h

Why Scientists Say This Personalized Cancer Vaccine Could Be a Game-Changer

An experimental mRNA cancer vaccine prevented the return and spread of melanoma, the deadliest form of skin cancer, in a large clinical trial, pharmaceutical companies Merck and Moderna announced this...

· 1d

From Covid to Cancer: How Moderna’s Stock Jumped 177% in a Day

· 1d

Cancer therapy breakthrough: Vaccine cuts skin cancer recurrence risk in landmark trial

· 1d

Moderna shares get a shot in the arm after cancer vaccine results

Elsewhere, the Evergrande saga came to a dramatic conclusion in a Shenzhen court.

· 1d

Merck and Moderna Say Cancer Vaccine Shows Promise in Preventing Recurrence of Melanoma

· 1d

What Is The Merck-Moderna Cancer Vaccine? All About The mRNA Shot That Could Be Built From Your Own Tumour

COVID-era juggernaut Moderna spikes 177% after successful late-stage trial for melanoma drug

Moderna has been looking for its next blockbuster drug after a wildly successful COVID era.

Moderna Shares Skyrocket 125% Toward Best Day Ever—On Success Of Cancer Drug Trial

Shares of Moderna rocketed by 93% to around $121.90 on Wednesday, pacing what would be the stock’s best-ever trading session after surging by more than 100% in premarket trading. That came after Moderna and Merck announced their personalized cancer vaccine helped cut the recurrence of melanoma—a form of skin cancer—in a late-stage trial involving more than 1,

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene (intismeran;